GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » Other Income (Expense)

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Other Income (Expense) : NT$-0.42 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Great Novel Therapeutics Biotech & Medicals Other Income (Expense)?

Great Novel Therapeutics Biotech & Medicals's other income expense for the Great Novel Therapeutics Biotech & Medicals's pretax income for the six months ended in Dec. 2023 was NT$-0.43 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-0.42 Mil.

Great Novel Therapeutics Biotech & Medicals Other Income (Expense) Historical Data

The historical data trend for Great Novel Therapeutics Biotech & Medicals's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Great Novel Therapeutics Biotech & Medicals Other Income (Expense) Chart

Great Novel Therapeutics Biotech & Medicals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Income (Expense)
Get a 7-Day Free Trial 0.45 -1.39 0.15 0.72 -0.42

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.18 0.52 0.20 0.01 -0.43

Great Novel Therapeutics Biotech & Medicals Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-0.42 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Great Novel Therapeutics Biotech & Medicals  (ROCO:7427) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » Other Income (Expense)
Comparable Companies
TPE:1733 ROCO:4194 ROCO:4724 ROCO:6564 ROCO:4130 ROCO:6580 ROCO:4168 ROCO:4911 ROCO:6879 ROCO:6926 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503
Website
http://www.gntbm.com.tw
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Headlines

No Headlines